Experience
Principia Biopharma
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million. Sanofi agreed to pay $3.7 billion to acquire Principia.
Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement
Eisai Co., Ltd.
Finnegan plays key role in $2.35B technology acquisition
ARRIS Group, Inc.
Startup sold to major drug company based on strength of patents
Agouron Pharmaceuticals, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.